Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine.
- Author:
Bei-zhan NIU
1
;
Ge CHEN
;
Li-jun LI
;
Yuan-de WU
;
Yu-Pei ZHAO
Author Information
- Publication Type:Journal Article
- MeSH: Antimetabolites, Antineoplastic; pharmacology; Cell Line, Tumor; Deoxycytidine; analogs & derivatives; pharmacology; Drug Resistance, Neoplasm; drug effects; Humans; Pancreatic Neoplasms; enzymology; pathology; Thioredoxin-Disulfide Reductase; drug effects; metabolism
- From: Acta Academiae Medicinae Sinicae 2005;27(5):606-610
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo establish gemcitabine-resistant pancreatic cancer cell strain and study the role of thioredoxin reductase (TrxR) in drug-resistant process.
METHODSGemcitabine-resistant pancreatic cancer cell strain SW1990/GZ was induced by increasing drug dosage intermittently, then the changes of its biological features and the activity of TrxR were examined.
RESULTSStable drug-resistant SW1990/GZ cell strain was established by culturing with gemcitabine for 9 months. The morphology and growth characteristics of the cell strain changed remarkably. The cells shrunk and became rounder; its endoplasm expanded; granular substances increased; and the doubling-time was prolonged. Resistance of the cell line to gemcitabine, fluorouracil, adriamycin, and mitomycin significantly increased. The TrxR activity of the drug-resistant cells was increased markedly.
CONCLUSIONSW1990/GZ has certain multidrug resistance to some chemotherapy drugs, and TrxR plays a role in the drug-resistant process.
